Loading
A phase 2 trial of Carboplatin, Bevacizumab, Olaparib in ovarian cancer, run by AbbVie, now recruiting.
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies is a phase 2 interventional study registered as NCT07024784 by AbbVie, with 377 participants planned, started 2025-07-30 and due to reach its primary completion in 2028-01. Interventions recorded: IMGN151, Carboplatin, Bevacizumab, Olaparib. Conditions listed: Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC). No results are recorded here; the registry entry is the source.
Shares AbbVie (incl. ImmunoGen, Capstan), Bevacizumab, Carboplatin, Ovarian cancer.
Shares AbbVie (incl. ImmunoGen, Capstan), Bevacizumab, Carboplatin, Ovarian cancer.
Shares AbbVie (incl. ImmunoGen, Capstan), Bevacizumab, Ovarian cancer.
Shares AbbVie (incl. ImmunoGen, Capstan), Carboplatin, Ovarian cancer.
Shares Olaparib, Ovarian cancer.
Shares Olaparib, Carboplatin, Ovarian cancer.
Shares Olaparib, Bevacizumab, Ovarian cancer.